Tecentriq + chemo increase OS, PFS in untreated extensive stage small cell lung cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Genentech said that the phase III IMpower133 study met its co-primary endpoints of overall survival and progression-free survival at its first interim analysis.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login